DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/2ctc38/kidney_cancer)
has announced the addition of Global Markets Direct's new report "Kidney
Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012" to their offering.
This report provides information on the therapeutic development for
Kidney Cancer (Renal Cell Cancer), complete with latest updates, and
special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Kidney
Cancer (Renal Cell Cancer).
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, Half Year is built
using data and information sourced from Global Markets Direct's
proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put
together by Global Markets Direct's team.
Scope
- A snapshot of the global therapeutic scenario for Kidney Cancer (Renal
Cell Cancer).
- A review of the Kidney Cancer (Renal Cell Cancer) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
- Coverage of the Kidney Cancer (Renal Cell Cancer) pipeline on the
basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics
under development for Kidney Cancer (Renal Cell Cancer).
- Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of
the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding
Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/2ctc38/kidney_cancer
Source: Global Markets Direct
